Last reviewed · How we verify
PEG-IFNa 2a
PEG-IFNa 2a is a pegylated form of interferon alpha-2a, which works by stimulating the body's immune system to fight viral infections and cancer cells.
PEG-IFNa 2a is a pegylated form of interferon alpha-2a, which works by stimulating the body's immune system to fight viral infections and cancer cells. Used for Chronic hepatitis C, Chronic hepatitis B, Multiple sclerosis.
At a glance
| Generic name | PEG-IFNa 2a |
|---|---|
| Sponsor | IRCCS San Raffaele |
| Drug class | Interferon |
| Target | IFNAR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Interferon alpha-2a is a protein that helps to activate immune cells, such as natural killer cells and T cells, to recognize and destroy infected cells or cancer cells. The pegylation of interferon alpha-2a allows it to be administered less frequently and with a longer duration of action, which can improve patient compliance and reduce side effects.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Multiple sclerosis
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Myalgia
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Depression
- Anxiety
Key clinical trials
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
- A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-IFNa 2a CI brief — competitive landscape report
- PEG-IFNa 2a updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI